Lupin has launched its Carbidopa Tablets 25mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin’s Carbidopa Tablets, 25mg is the generic equivalent of Aton Pharma, Inc.’s Lodosyn Tablets, 25 mg. It is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.
Carbidopa Tablets, 25mg had annual sales of around $17.4 million in the US (IQVIA MAT January 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
